A model to incorporate genetic testing (5-HTTLPR) in pharmacological treatment of major depressive disorders

Abstract Objective. To evaluate the benefit of pharmacogenetics in antidepressant treatment. Methods. In a simulated trial 100,000 subjects in a current episode of major depressive disorder (MDD) received citalopram or bupropion based on the clinician's decision (algorithm A) or following indic...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The world journal of biological psychiatry Ročník 12; číslo 7; s. 501 - 515
Hlavní autori:	Serretti, Alessandro, Olgiati, Paolo, Bajo, Emanuele, Bigelli, Marco, De Ronchi, Diana
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Informa Healthcare 01.10.2011 Taylor & Francis
Predmet:	antidepressants Antidepressive Agents - economics Antidepressive Agents - therapeutic use Bupropion - economics Bupropion - therapeutic use Citalopram - economics Citalopram - therapeutic use Computer Simulation cost-benefit Cost-Benefit Analysis - methods Depression Depressive Disorder, Major - drug therapy Depressive Disorder, Major - economics Depressive Disorder, Major - genetics Genetic Testing - economics Humans Meta-Analysis as Topic Models, Psychological pharmacoeconomics pharmacogenetics Pharmacogenetics - economics Pharmacogenetics - methods Serotonin Plasma Membrane Transport Proteins
ISSN:	1562-2975, 1814-1412, 1814-1412
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!